Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is an immuno-pharma company with a positive outlook due to potential catalysts from ongoing clinical trials, a focus on developing treatments for pancreatic cancer with promising results, and partnerships with major cancer research centers. Risks include balance sheet and liquidity issues, regulatory approvals, and competition. Despite these risks, the company has a strong balance sheet with enough cash to fund operations into late-2026 and a current valuation that presents an attractive opportunity for investors.

Bears say

AIM ImmunoTech is a biotech company with a strong focus on developing new drug therapies for viral and immune-related diseases. However, the company's limited pipeline and current lack of profitability, coupled with the uncertain timing of key clinical data release, make it a risky investment option. Further, the company's changing focus to pancreatic cancer may take some time to materialize into significant financial returns, possibly impacting stock performance in the near future.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.